CD33-CAR

CD33-CAR is a chimeric antigen receptor (CAR) T cell therapy in which autologous or allogeneic T cells are genetically modified to express a synthetic receptor targeting the CD33 antigen, a sialic acid-binding immunoglobulin-like lectin highly expressed on acute myeloid leukemia (AML) blasts and some other myeloid leukemias. Once infused into the patient, these engineered T cells recognize and bind to CD33 on tumor cells, resulting in targeted cytotoxicity. CD33-CAR T cell therapy has shown variable preclinical and early clinical efficacy, including in models with low antigen density, and is currently being actively investigated in phase I and ib trials for relapsed/refractory AML, including pediatric and young adult populations. Modifications and optimizations (e.g., membrane-proximal binders, drug-regulated switching) are under study to improve safety and efficacy and reduce off-tumor toxicity due to shared CD33 expression on normal myeloid cells[1][2][4][7][8].

Other names

CD33 CAR T cellCD-33 CAR T cellCD 33 CAR T cellanti-CD33 CAR T cellanti-CD-33 CAR T cellanti-CD 33 CAR T cellCD33 chimeric antigen receptor T cellCD-33 chimeric antigen receptor T cellCD 33 chimeric antigen receptor T cellCD33 CAR-TCD-33 CAR-TCD 33 CAR-T